Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378002 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL7257964 | 0.87 | RAB9A (0.51) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL5694862 | 0.86 | MEN1 (0.43) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL29435026 | 0.85 | HDAC3 (0.58) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL222876 | 0.85 | HDAC3 (0.58) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7439456 | 0.84 | HDAC3 (0.57) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4254852 | 0.82 | GAA (0.60) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13710304 | 0.82 | GAA (0.51) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL31606834 | 0.82 | GAA (0.63) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL8191789 | 0.82 | RXFP1 (0.50) | ALDH1A1MAPTNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| EP-4192825-A2 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192504-A2 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| EP-2677318-B1 | LABELING AGENT FOR POST-TRANSLATIONAL MODIFICATION ANALYSIS OF SERINE AND THREONINE | CELLSEED INC (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2677318-B1 | LABELING AGENT FOR POST-TRANSLATIONAL MODIFICATION ANALYSIS OF SERINE AND THREONINE | CELLSEED INC (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20140024124-A1 | LABELING AGENT FOR ANALYZING POST-TRANSLATIONAL MODIFICATIONS OF SERINE AND THREONINE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2014-01-23 | — | — | US | disclosed |
| EP-2677318-A1 | LABELING AGENT FOR POST-TRANSLATIONAL MODIFICATION ANALYSIS OF SERINE AND THREONINE | CellSeed Inc. (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114471-A1 | NOVEL AMIDE DERIVATIVES OF STEROIDAL[3,2-C]PYRAZOLE COMPOUNDS WITH GLUCOCORTICOID ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| EP-0614898-B1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6291470-B1 | DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION | TORAY INDUSTRIES, INC. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6087369-A | AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT | TORAY INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| CN-1043766-C | Indole derivative and preparation and pharmaceutical using of same | TORAY INDUSTRIES (JP) | 1999-06-23 | — | — | CN | disclosed |
| US-5852030-A | Indole derivatives, process for producing the same and medicinal uses of the same | TORAY INDUSTRIES, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| CN-1092425-A | Indole derivatives, its manufacture method and medicinal use thereof | TORAY INDUSTRIES (JP) | 1994-09-21 | — | — | CN | disclosed |
| EP-0614898-A1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | BET1, BRD4, BAZ2A | ALDH1A1 4266/4885MAPT 3174/4885NPC1 3631/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | ALDH1A1 2592/4885MAPT 3111/4885NPC1 3588/4885 |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | H1-4, H1-3, H1-5 | ALDH1A1 1751/4885MAPT 3420/4885NPC1 2071/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | ALDH1A1 4450/4885MAPT 2862/4885NPC1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.